{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:26:08Z","timestamp":1789244768906,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","award":["GSK214891"],"award-info":[{"award-number":["GSK214891"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RO1 DK123262 (M\u202fE\u202fG"],"award-info":[{"award-number":["RO1 DK123262 (M\u202fE\u202fG"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaut.2022.102897","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T07:07:44Z","timestamp":1661324864000},"page":"102897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Dual B-cell targeting therapy ameliorates autoimmune cholangitis"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-6851","authenticated-orcid":false,"given":"Weici","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.C.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Tsuneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Heuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2022.102897_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.13347","article-title":"Emerging novel treatments for autoimmune liver diseases","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jaut.2022.102897_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-014-8456-5","article-title":"New therapies for primary biliary cirrhosis","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.autrev.2016.07.003","article-title":"Novel therapeutics for primary biliary cholangitis: toward a disease-stage-based approach","volume":"15","author":"Mousa","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2022.102897_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.2015.998650","article-title":"Advances in pharmacotherapy for primary biliary cirrhosis","volume":"16","author":"Mousa","year":"2015","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.jaut.2022.102897_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The challenges of primary biliary cholangitis: what is new and what needs to be done","volume":"105","author":"Terziroli Beretta-Piccoli","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2022.102897_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: an orchestrated immune response against epithelial cells","volume":"174","author":"Gershwin","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2022.102897_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1084\/jem.20010956","article-title":"Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells","volume":"195","author":"Kita","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2022.102897_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1006\/jaut.1998.0220","article-title":"Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis","volume":"11","author":"Malmborg","year":"1998","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2022.102897_bib11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/hep.27313","article-title":"Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.13554","article-title":"Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis","volume":"38","author":"Tan","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.jaut.2022.102897_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coi.2021.06.014","article-title":"BAFF signaling in health and disease","volume":"71","author":"Schweighoffer","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib14","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s10620-016-4317-9","article-title":"B cell-activating factor (BAFF)-Targeted B cell therapies in inflammatory bowel diseases","volume":"61","author":"Uzzan","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jaut.2022.102897_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41467-018-03620-2","article-title":"BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus","volume":"9","author":"Shin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2022.102897_bib16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102897_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/jgh.13534","article-title":"Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis","volume":"32","author":"Tang","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2022.102897_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2022.102897_bib19","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2022.102897_bib20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2022.102897_bib21","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib22","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102897_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/ker526","article-title":"B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels","volume":"51","author":"Lazarus","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2022.102897_bib24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102897_bib25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102897_bib26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102897_bib27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4(+) T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2022.102897_bib28","first-page":"73","article-title":"Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: the phase 3, randomized, placebo-controlled BLISS-BELIEVE study [abstract]","author":"Aranow","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2022.102897_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/hep.28641","article-title":"Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance","volume":"64","author":"Bae","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/hep.29524","article-title":"The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity","volume":"67","author":"Bae","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib31","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.25829","article-title":"Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice","volume":"57","author":"Tsuda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/cmi.2017.149","article-title":"Proteomic analysis reveals distinctive protein profiles involved in CD8(+) T cell-mediated murine autoimmune cholangitis","volume":"15","author":"Zhang","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.31724","article-title":"Enoxacin up-regulates MicroRNA biogenesis and down-regulates cytotoxic CD8 T-cell function in autoimmune cholangitis","volume":"74","author":"Itoh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41423-019-0199-z","article-title":"Liver-resident NK cells suppress autoimmune cholangitis and limit the proliferation of CD4(+) T cells","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib35","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.celrep.2019.04.019","article-title":"FCRL5(+) memory B cells exhibit robust recall responses","volume":"27","author":"Kim","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jaut.2022.102897_bib36","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.174.7.4389","article-title":"The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice","volume":"174","author":"Hamaguchi","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.23238","article-title":"B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice","volume":"50","author":"Moritoki","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/hep.24044","article-title":"B cell depletion therapy exacerbates murine primary biliary cirrhosis","volume":"53","author":"Dhirapong","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2022.102897_bib39","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/S0140-6736(18)30984-X","article-title":"Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial","volume":"391","author":"Banham","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2022.102897_bib40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102897_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus - past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102897_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/art.38907","article-title":"Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus","volume":"67","author":"Lin","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2022.102897_bib43","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib44","first-page":"311","article-title":"Ultrasound assessment of salivary glands in patients with primary Sjogren's syndrome treated with rituximab: quantitative and Doppler waveform analysis","volume":"1","author":"Jousse-Joulin","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.jaut.2022.102897_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2249.2010.04301.x","article-title":"B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism","volume":"163","author":"Ueki","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib46","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","article-title":"Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment","volume":"56","author":"Teng","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102897_bib47","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2022.102897_bib48","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2022.102897_bib49","first-page":"118","article-title":"CD20 as a gatekeeper of the resting state of human B cells","author":"Klasener","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2022.102897_bib50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/eji.1830230330","article-title":"CD20 monoclonal antibodies down-regulate IgM at the surface of B cells","volume":"23","author":"Bourget","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib51","first-page":"218","article-title":"Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival","author":"Muller-Winkler","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2022.102897_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramskold","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaut.2022.102897_bib53","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102897_bib54","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.4049\/jimmunol.1202860","article-title":"Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors","volume":"190","author":"Franco","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2022.102897_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0211096","article-title":"Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes","volume":"91","author":"Dement-Brown","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2022.102897_bib56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.immuni.2019.12.005","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"52","author":"Jenks","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2022.102897_bib57","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1038\/s41598-022-08976-6","article-title":"Interferon-gamma signal drives differentiation of T-bet(hi) atypical memory B cells into plasma cells following Plasmodium vivax infection","volume":"12","author":"Kochayoo","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:30:40Z","timestamp":1760257840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841122001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":57,"alternative-id":["S0896841122001056"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102897","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual B-cell targeting therapy ameliorates autoimmune cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102897"}}